[ad_1]
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biopharmaceutical company, today announced the pricing of its expanded initial public offering of 19,000,000 shares of common stock at a public offering price of $16.00 per share. Caribou provides all common shares. Before deducting underwriting discounts and commissions and other issuance fees payable by Caribou, the total proceeds from the issuance are estimated to be US$304 million. In addition, Caribou has granted the underwriters a 30-day option to purchase up to 2,850,000 common shares at the initial public offering price minus underwriting discounts and commissions.
These stocks are expected to begin trading on the Nasdaq Global Select Market on July 23, 2021, under the ticker symbol “CRBU”. The issuance is expected to be completed on or about July 27, 2021, subject to customary closing conditions.
Bank of America Securities, Citigroup and SVB Leerink will serve as joint bookrunners for this offering.
The United States Securities and Exchange Commission (“SEC”) announced on July 22, 2021 that the registration statement related to this issuance became effective. The issuance was only conducted through the prospectus. …
The full story can be found on Benzinga.com
[ad_2]
Source link
